At ESMO 2024, Amanda Nizam, MD, from the Cleveland Clinic and Jørgen Bjerggaard Jensen, MD, from Aarhus University discuss the TOMBOLA trial, assessing early post-cystectomy immunotherapy according to ctDNA status in muscle-invasive bladder cancer. Dr. Jensen highlights the single-arm trial design, details the trial’s use of ctDNA, and elaborates on how TOMBOLA fits into the larger context of other trials in bladder cancer. ...
Urothelial Carcinoma Diagnostics
Advertisement
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Advertisement
Video Insights
Conference Coverage
Dr. Daneshmand talks about key studies and exciting developments in bladder cancer from the LUGPA 2024 Annual Meeting.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.